Novo Nordisk A/S (NVO)

45.80
0.39 0.84
NYSE : Health Technology
Prev Close 46.19
Open 45.97
Day Low/High 45.08 / 46.12
52 Wk Low/High 41.23 / 58.37
Volume 1.83M
Avg Volume 1.67M
Exchange NYSE
Shares Outstanding 2.01B
Market Cap 113.44B
EPS 2.30
Div & Yield 0.91 (1.96%)

Latest News

Stocks Mixed as Asia Gets China Trade Boost, Wall Street Rides Earnings Wave

Stocks Mixed as Asia Gets China Trade Boost, Wall Street Rides Earnings Wave

Global stocks were mixed Wednesday, with stronger-than-expected trade data from China, as well as the expectation of further stimulus from Beijing, boosting shares in Asia while softer earnings in Europe held down gains for stocks on the Continent.

Exiting Eli Lilly Position

We are taking a win, closing our LLY position and minimizing risk just a few days before it reports second-quarter earnings.

Tresiba® Demonstrated Significantly Improved Blood Sugar Control And Lower Rates Of Hypoglycemia Versus Insulin Toujeo® In Real-world Evidence Study

Tresiba® Demonstrated Significantly Improved Blood Sugar Control And Lower Rates Of Hypoglycemia Versus Insulin Toujeo® In Real-world Evidence Study

Adults with type 2 diabetes treated with Tresiba ® (insulin degludec injection) had a significant reduction in HbA 1c and a 30 per cent lower rate of hypoglycemic episodes compared with those treated with Toujeo ® (insulin glargine U300) after starting...

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.

Novo Nordisk Stock Rises 4% Over 2 Sessions

Novo Nordisk Stock Rises 4% Over 2 Sessions

Pharma firm's new diabetes drug showed positive test results.

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

The Danish company's shares are enjoying their best day since May 2.

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.

Buying More Lilly

We are picking up LLY shares into weakness, below our basis in the process.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

BMO Capital Markets analyst Alex Arfaei says the fourth-quarter results show how dependent the drugmaker is on major diabetes assets 'and doesn't alleviate our concerns.'

Novo Boosts Exploration Team

Novo Boosts Exploration Team

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.

Comet Well Tenements Granted

Comet Well Tenements Granted

Novo Provides Corporate Update

Novo Provides Corporate Update

TheStreet Quant Rating: B- (Buy)